 |
|
| PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
| |
| | |
|
|
 An International Research, Review, and News Journal
Editor-in-Chief:
G. Drolet
See editorial board for all editors information
Description
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary
research, review and news journal. One of its main aims is to assure rapid publication of authoritative reviews and research papers dealing
with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Another important aim of the journal is
to supply pertinent information, provided by national and international bodies, that contributes to progress in the scientific and professional
fields. Finally, the journal intends to foster and encourage communications between members of the communities of neuro-psychopharmacology
and biological psychiatry.
US National Institutes of Health (NIH) voluntary posting ("Public Access") policy
Progress
in Neuropsychopharmacology & Biological Psychiatry and Elsevier facilitate the author's response to the NIH Public Access Policy.
For more details please see the Guide
for authors
Fraudulent 'phishing' e-mails soliciting scholarly papers have been circulating which claim to originate
from Elsevier, Inc. and are directed to prospective authors and editors.
The fraudulent e-mail messages currently in circulation
generally contain "Manuscript Submission" or "Call for Papers" in the subject line and are typically sent using e-mail accounts supported
by Gmail, Hotmail or by other free e-mail providers. Typically, the body of these messages contain a "Call for Papers," requesting that
authors submit scholarly articles via e-mail for publication by Elsevier in various Elsevier journals and other publications. Ultimately,
these fraudulent e-mails involve a request for the victims to send "handling fees" to cover the processing of the article that has been
submitted.
Please be assured that Elsevier, Inc. is in no way associated with this fraudulent e-mail campaign. In addition, please
be advised that Elsevier does not solicit intellectual property from authors in this fashion, and does not utilize Gmail,
Hotmail, or any other free third-party e-mail providers in communications with authors and editors.
If you receive any e-mail messages
that appear to be a part of this fraudulent solicitation, DO NOT respond to the message and do not open any attachments
contained in the message. Rather, please forward the message to Elsevier's Fraud Department at emailabuse@elsevier.com.
We will use the information included in the message to aid in our investigation.
| Bibliographic details |
ISSN: 0278-5846
Imprint: ELSEVIER
Commenced publication 1977
Subscriptions for the year 2009,
Volume 33,
8 issues |
| Price and Ordering |
Institutional online access: ScienceDirect eSelect
For purchase of online access to this journal on ScienceDirect.
|
Personal price:
USD 379 for all countries except Europe, Japan and Iran
EUR 339 for European countries and Iran
JPY 44,900 for Japan
|  |
Institutional price:
EUR 2,082 for European countries and Iran
JPY 276,600 for Japan
USD 2,329 for all countries except Europe, Japan and Iran
| |
Conditions of sale & ordering procedures, and links to our regional sales offices.
|
For an overview of recently-dispatched issues, see the Journal issue
dispatch dates
Audience
Neuroscientists, pharmacologists, psychiatrists, psychologists in both basic and clinical research.
Impact factor of this journal
2007: 2.802
© Journal Citation Reports 2008, published by Thomson Reuters
603/195
Last update: 2 Oct 2008
|
|
| |
| | |
|
|
| |
